The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically been dominated by chemotherapies. These agents have become fully integrated into current treatment practices for unresectable locally advanced or metastatic bladder cancer. Biomarker-driven treatments are becoming increasingly attractive, as highlighted by Balversa’s FDA approval in April 2019. Given the intense Phase II/III pipeline activity, we anticipate the approval of several new therapies for both muscle-invasive and non-muscle-invasive bladder cancer within the forecast period.
Geographies: United States, EU5, Japan.
Primary Research: 20 country-specific interviews with thought-leading urologists and medical oncologists. Supported by survey data collected for this and other DRG research.
Epidemiology: Diagnosed and recurrent incidence of bladder cancer by country, segmented by clinically and commercially relevant drug-treatable populations.
Forecast: Ten-year, annualized, drug-level sales and patient share of key bladder cancer therapies through 2028, segmented by brands/generics and epidemiological subpopulations.
Emerging Therapies: Phase III/PR: 6 drugs; Phase II: 10 drugs; coverage of select preclinical and Phase I products.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.